Metabolic and Microbial Profiling of Lung Cancer
This pilot study will establish non-invasive sample collections, including breath, saliva, blood and urine pre-surgery and at the participant's one-month post-surgery follow-up visit. Participants with suspected non-small cell lung cancer (NSCLC) stage I-III will be recruited.
Checked against the public recordLast updated Nov 5, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Other: Breath Collection; Other: Saliva Collection; Other: Blood Collection; Other: Urine Collection; Other: Tumor Collection; Other: Medical History Data Collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Male and female patients age \>18 years, of all racial and ethnic origins, with suspected nonsmall cell lung cancer stages I, II, and III, as evident through radiographic evidence and felt acceptable to undergo surgical resection. * Patients who have the ability to understand and the willingness to sign a written consent form. Exclusion Criteria: * Patients who are have taken antibiotics within two weeks. * Patients who are on continuous supplemental oxygen. * Patients currently undergoing active treatment for other malignancies. * Subjects who are unable or unwilling to provide consent.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 5, 2021. Always confirm current availability with the study team.